Parameter
| Biomarker | MSLN | Full name | Mesothelin | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis |
| Disease | Ovarian Cancer | Disease Subtypes | / | ||
| Organ | Ovary | Test Sample / Technology Platform | Serum / Tumor Tissue (ELISA, IHC, Flow Cytometry) | ||
| Pathobiological Mechanisms | It mediates the adhesion between tumor cells and stromal cells, promoting tumor invasion and metastasis. The positive expression rate in ovarian cancer tissues is 70% - 80%. | ||||
| Clinical Availability Status | In the process of research verification / clinical translation: IHC is used for tissue detection, while serum testing is in the stage of large-scale validation. | ||||
| Notes and Dynamics | The supplementary diagnostic sensitivity for CA125-negative ovarian cancer is 65%; as an immunotherapy target, the MSLN-targeted antibody-drug conjugate (ADC) has entered phase II clinical trials. | ||||